NomiMetabolism Secures Hundreds of Millions RMB in Series A Funding to Advance Integrated Clinical Mass Spectrometry and Metabolomics Solutions

Suzhou Panomics Biomedical Technology Co., Ltd. (abbreviated as: Nuomi Metabolism)Recently announced the completion of a RMB 100 million Series A financing round, led by YuanBio Venture Capital, with Gelu Capital serving as the exclusive financial advisor. The funds raised in this round will be used for the expansion of the company’s technology platform, the development of clinical mass spectrometry kits, and the research and development of metabolomics clinical products.

Nuomi Metabolomics received seed funding from Mint Angel Fund and Suzhou Junshi Biosciences in 2016, and secured Series A financing led by Wosheng Investment in 2018. As one of the earliest established and largest metabolomics companies in China, it is a leader in the metabolomics research services market and the first Chinese metabolomics company to engage in the development of clinical and health products.

Leveraging its comprehensive sample pretreatment platform, high-resolution mass spectrometry platform, extensive metabolite library with core matching algorithms, and the proprietary cloud-based data analysis system BioDeep™, Nuomi Metabolism has served over 400 research institutes and universities both in China and abroad,Providing comprehensive and professional metabolomics services to over 300 Grade A tertiary hospitals as well as food and pharmaceutical companies. Our service offerings encompass untargeted metabolomics, targeted metabolomics, comprehensive targeted panels, lipidomics, flavoromics, as well as spatial and single-cell metabolomics. Application areas include research fields related to oncology, cardiovascular diseases, metabolic disorders, and gut microbiota, covering more than 80 specialized testing and analytical services to provide customers with personalized metabolomics solutions for both scientific research and clinical applications. With the expansion of metabolomics applications in the broader health sector, the company’s clinical metabolomics business is poised for explosive growth.

Nuomi Metabolomics’ metabolomics platform, based on mass spectrometry quantitative technology, has significantly advanced the implementation of clinical mass spectrometry services within the company. With a blue-ocean market in China valued at tens of billions of RMB, Nuomi Metabolomics’ strong strategic presence in mass spectrometry diagnostic kits and medical laboratory testing positions it to become a comprehensive solution provider for clinical mass spectrometry and metabolomics.

Currently, Nuomi Metabolism operates more than 60 imported mass spectrometry instruments across its laboratories in Suzhou, Nanjing, Nanchang, and Chengdu. Among these, clinical mass spectrometry offers high throughput and short turnaround times, enabling the company to provide customers with higher-quality and faster clinical testing services. The company has registered nearly 20 clinical mass spectrometry assay kits, covering routine clinical mass spectrometry tests as well as the clinical application of innovative metabolite markers. This round of financing will enable Nuomi Metabolism to enhance its medical testing laboratories and expand its portfolio of clinical mass spectrometry assay kits, thereby providing more convenient, efficient, and accurate mass spectrometry testing solutions for clinical applications.

Nuomi Metabolism’s Clinical Metabolomics Solution is a novel technological platform that employs mass spectrometry and systems biology approaches to identify metabolites applicable for clinical diagnosis. By monitoring and identifying differential metabolites between healthy individuals and patients with specific diseases, this solution provides critical evidence for disease diagnosis and prevention, selection of patient populations for clinical medication, and decision-making regarding the timing of drug administration.

Nuomi Metabolism’s innovative metabolomics clinical technology platform—MetaDiscovery™,It can complete a full scan of tens of thousands of metabolites in clinical samples within ten minutes. By leveraging self-developed algorithms—including the BioDeepDB metabolite database, compound matching, isotope quantification, and deep learning—and by integrating structured electronic medical records, pathology, and imaging data, it constructs an ontological multi-dimensional cross-data technology platform. This significantly enhances diagnostic accuracy and promotes metabolomics as the gold standard for clinical diagnosis.

Leveraging years of expertise and accumulation in the field of clinical metabolomics, Nuomi Metabolism has established a product development pipeline that includes diagnostics for non-obstructive coronary artery disease (NOCA), primary prevention of stroke, and companion diagnostics for antibody drugs in collaboration with Suzhou Alphamab Oncology. The relevant test kits are expected to receive regulatory approval sequentially.

Ren Jianhong, Founder and CEO of Nuomi Metabolism“With strong support from lead investor YuanBio Venture Capital, this round of financing will accelerate our strategic layout and development in technical services, clinical mass spectrometry, and omics-based clinical applications, ensuring Nuomi Metabolism maintains its leading position in the research, development, and application of metabolomics technologies. We remain steadfast in our commitment to creating value for clinical practice and public health through metabolomics. Our top priority is the development and implementation of a precision platform that integrates high-throughput omics technologies with structured clinical data. Guided by our vision to ‘aim high while staying grounded,’ we strive to become everyone’s personal metabolic health manager.”

Dr. Lin Yi, Partner at YuanBio Venture CapitalIt stated: “Compared with developed countries, clinical mass spectrometry testing in China remains a blue-ocean market within the in vitro diagnostics industry, and clinical mass spectrometry testing is precisely a niche segment of clinical metabolomics. Nuomi Metabolism is a pioneer in China’s clinical metabolomics field and one of the establishers of industry standards. The founder, Ren Jianhong, has profound expertise and insightful vision in the field of clinical metabolomics. We look forward to Nuomi Metabolism’s successful efforts in clinical mass spectrometry and omics-based clinical applications, providing more precise services to physicians and patients, and becoming a globally leading enterprise in clinical metabolomics.”

YuanBio Venture Capital is a healthcare-focused investment firm specializing in early-stage and growth-stage companies. Headquartered at Suzhou BioBAY, it maintains a global reach. With approximately RMB 6 billion in assets under management, YuanBio has invested in over 100 high-quality projects spanning new drug development, medical devices, in vitro diagnostics (IVD), and healthcare services, delivering substantial returns. The firm has been repeatedly recognized as one of the Top 10 Venture Capital Funds in China’s healthcare sector and as one of the most active healthcare investors in the country. YuanBio brings together a team of seasoned professional investors and world-class scientific advisors, leveraging extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. By focusing on its core strengths and leveraging rich industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.